Menu
Log in
Forgot password
Log in
Forgot password

News

  • Home
  • Resources
  • Literature Updates
  • Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study

Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study

22 Nov 2024 4:08 PM | Anonymous member (Administrator)

Tongpeng Xu, Jianan Bai, Kun Zhao, Xiaofeng Chen, Shuhui Wang, Shusheng Zhu, Chongqi Sun, Chenhui Zhao, Ting Wang, Ling Zhu, Meizhen Hu, Fei Pang, Junling Zhang, Wei Wang, Yongqian Shu, Fang Li & Yue Zhou

Read Abstract: Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software